Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine
Data(s) |
01/12/2015
|
---|---|
Resumo |
Genomic cancer medicine promises revolutionary change in oncology. The impacts of 'personalized medicine', based upon a molecular classification of cancer and linked to targeted therapies, will extend from individual patient outcomes to the health economy at large. To address the 'whole-of-system' impact of genomic cancer medicine, we have established a prospective cohort of patients with newly diagnosed cancer in the state of Victoria, Australia, about whom we have collected a broad range of clinical, demographic, molecular, and patient-reported data, as well as data on health resource utilization. Our goal is to create a model for investigating public investment in genomic medicine that maximizes the cost:benefit ratio for the Australian community at large. |
Identificador | |
Idioma(s) |
eng |
Publicador |
Elsevier |
Relação |
http://dro.deakin.edu.au/eserv/DU:30079609/ashley-cancer2015-inpress-2015.pdf http://dro.deakin.edu.au/eserv/DU:30079609/ashley-cancer2015longitudinal-2015.pdf http://www.dx.doi.org/10.1016/j.drudis.2015.10.009 http://www.ncbi.nlm.nih.gov/pubmed/26494144 |
Direitos |
2015, Elsevier |
Tipo |
Journal Article |